Abstract
Although the COVID-19 disease burden is heterogeneous across space, the U.S. National Academies of Sciences, Engineering, and Medicine recommends an equitable spatial allocation of pharmaceutical interventions based, for example, on population size, in the interest of speed and workability. Utilizing economic–epidemiological modeling, we benchmark the performance of ad hoc allocation rules of scarce vaccines and drugs by comparing them to the rules for a vaccine and for a drug treatment that minimize the economic damages and expenditures over time, including a penalty cost representing the social costs of deviating from an ad hoc allocation. Under different levels of vaccine and drug scarcity, we consider scenarios where length of immunity and compliance to travel restrictions vary, and consider the robustness of the rules when assumptions regarding these factors are incorrect. Because drugs and vaccines attack different points in the disease pathology, the benefits from deviating from the ad hoc rule differ. For drug treatment, optimal policies often allocate all available treatments to one jurisdiction for a period of time, while ad hoc rules act to spread out treatments across jurisdictions. For vaccines, the benefits from deviating are especially high when immunity is permanent, when there is compliance to travel restrictions, and when the supply of vaccine is low. Interestingly, a lack of compliance to travel restrictions pushes the optimal allocations of vaccine towards the ad hoc and improves the relative robustness of the ad hoc rules, as the mixing of the populations reduces the spatial heterogeneity in disease burden.
Antiviral Drugs
Spatial Prioritization: Drugs should be directed towards the region that has fewer infections; optimal allocation gives rise to extreme allocations where it is preferable to give all of the allotment to one jurisdiction for a period of time rather than an allocation based on relative levels of infected individuals.
Epidemiological Consequences of Spatial Prioritization: Compared to the ad hoc allocation rule, where more treatments go to locations with more infected individuals, the optimal allocation results in a higher number of cumulative cases in the jurisdictions that have a higher initial level of infected individuals and fewer cumulative cases in the jurisdictions that have a lower initial level of infected individuals. Over the period of four months, however, how well the optimal more extreme allocation does in aggregate (across jurisdictions) relative to an aggregate ad hoc allocation is dependent on epidemiological, behavioral, and logistical factors.
Robustness of Spatial Allocation: The optimal allocations are not robust to incomplete information on compliance to travel restrictions and immunity, and perform worse than the ad hoc allocations in cases where they are designed under one set of assumptions but yet the true state of the world is different.
Policy Recommendation: Until we have more information about compliance and immunity, our analysis leads us to conclude that ad hoc allocations may be the least risky option for the allocation of antiviral drugs.
Vaccines
Spatial Prioritization: Compared to an ad hoc allocation rule based on relative population size as recommended by the US National Academies of Science, Engineering, and Medicine, the optimal allocation of vaccine favors the least-burdened jurisdiction, resulting in an unequal distribution from a resource allocation perspective.
Epidemiological Consequences of Spatial Prioritization: The optimal allocation results in a more equal level of infection across jurisdictions in each period while the ad hoc allocation results in a more equal distribution of aggregate cumulative infections.
Robustness of Spatial Allocation: In terms of economic expenditures and cumulative cases, the optimal allocation is less impacted when assumptions on immunity are incorrect than when wrong about compliance to travel restrictions.
Policy Recommendation: Imposing strict travel restrictions, or e.g. forcing quarantine when traveling to another jurisdiction, and prioritizing vaccination in jurisdictions that have lower initial disease burden could prevent a significant number of cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
F.M.C. acknowledges funding from the Henry A. Jastro Graduate Research Scholarship Award. K.S and E.H. acknowledge funding from the Huck Institutes for the Life Sciences at The Pennsylvania State University. J.N.S. is a member of the Giannini Foundation of Agricultural Economics and acknowledges support from National Institute of Food and Agriculture (CA-D-ESP-7853-H).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No human or animal subjects were involved in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* Authors’ contributions: F.M.C. and J.N.S. designed and performed the research, conceived and developed the analysis, F.M.C., J.C.B, E.H., and K.S. developed the epidemiological model, F.M.C. and E.H. parameterized the model, and F.M.C. ran the simulations. All gave feedback on the preliminary findings. F.M.C. wrote the first draft of the paper. All contributed to the final version.
† We thank for useful comments participants of the NatuRE Policy Lab at UC Davis (naturepolicy.ucdavis.edu) and participants of the internal seminars at Université du Québecà Montréal (UQAM).
‡ For the code used in this paper, see: https://github.com/fmcastonguay/SpatialAllocationCOVID19
Version 3 (note there are no changes to the text): 1- Removed the "M" that appeared for some reason in the ORCID ID of author Katriona Shea, although it does not appear (as it should) anywhere else. 2- Moved the significance statement and key takeaways pages after title page so that the title page comes first.
7 Calibrated using a R0 estimate from (and estimates of effects of nonpharmaceutical interventions from Tian et al. 2020) Li et al. (2020); this yields a R0 of approximately 1.4 when there is compliance to travel restrictions and to match a R0 of approximately 2.1 when there is no compliance to travel restrictions; these two values representing respectively a “medium” and “low” effect of the nonpharmaceutical intervention.
8 Using estimates from Davies et al. (2020); this represents a 3-day latency period and a 5-day recovery period.
9 Representing a 6-month immunity period in the scenarios where we assume immunity is not permanent; based on Edridge et al. (2020).
10 Calibrated by using a case-fatility rate of 1.78% (adjusted for mis- and under-reporting; see Abdollahi et al., 2020).
11 Representing the disability associated with severe lower respiratory tract infections because, to our knowledge, there are no official Nurchis et al. disability estimates associated with COVID-19; see (2020).
12 According to the U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), and Center for Drug Evaluation and Research (CDER) (2019), there is no required effectiveness for a newly developed drug, however, what is necessary is that: “it is well established that the effect shown in the adequate and well-controlled clinical investigations, must be, in FDA’s judgment, clinically meaningful.” As a result, and to be consistent across both types of pharmaceutical interventions, we assume in the base case the effectiveness of the drug is 0.65.
13 Following Buckner et al 2020, we base this parameter value on the efficiency of the influenza vaccine (see Ohmit et al.,2014). U.S. Department of Health and Human Services, Food and Drug Administration (FDA), and Center for Biologics Evaluation and Research (CBER) (2020) requires that a future COVID-19 vaccine must have an effectiveness of at least 50%.
14 Based on results from John et al. (2019) that suggest a yearly discount rate between 0.3% and 1.5% for health related expenditures; we chose a 1.5% annual discount rate in the main set of results. This gives a monthly discount rate of r = 0.0013.
15 Based on current expectations of the costs of REGN-COV2, the medicine produced by Regeneron that President Trump took following his COVID-19 diagnosis. According to information from U.S. Food and Drug Administration (FDA), CBS News, and Regeneron, the drug is expected to cost between $1,500 and $6,500 depending on the exact number of doses required by a patient; see: https://www.cbsnews.com/news/what-is-regeneron-covid-antibody-cocktail-trump-covid-19/.
16 Assuming an individual requires two doses; based on current agreements between the U.S. federal government and biotech companies; see https://www.npr.org/sections/health-shots/2020/08/06/899869278/prices-for-covid-19-vaccines-are-starting-to-come-into-focus. For a list of current vaccine prices, and particularly the price of the influenza vaccine, see https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html.
17 Value based on a certain proportion of the value of statistical life, c; in the base case we assume it is 2 orders of magnitude smaller. Protection Agency
18 Represents a value of statistical life of 10M U.S. dollars. Based on the value of a statistical life that the U.S. Environmental (2020) uses: approximately $7.4 million ($2006) which is equivalent to approximately $9.54 million ($2020).
Data Availability
The parameter values used to run the numerical simulations are publicly available from the citations included in the text.
